102 results match your criteria: "the Ben-Gurion University of the Negev[Affiliation]"
J Cardiothorac Surg
December 2024
Department of Cardiology, Barzilai Medical Center, The Ben-Gurion University of the Negev, Hahistadrout 2, 7830604, Ashkelon, Israel.
Background: Giant coronary artery aneurysms are rare conditions with potentially devastating consequences. We report a case of the largest documented giant right coronary artery (RCA) aneurysm to date.
Case Presentation: A 57-year-old male patient visited our outpatient clinic for abdominal pain and exertional dyspnea.
Clin Infect Dis
December 2024
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Background: Nirsevimab is an extended half-life, highly potent neutralizing monoclonal antibody against the respiratory syncytial virus (RSV) fusion protein, with efficacy in preventing RSV-associated medically attended (MA) lower respiratory tract infection (LRTI) in infants and medically vulnerable children (aged ≤24 months). This post-hoc exploratory analysis examined the incidence of LRTI from RSV and other respiratory pathogens during a 2:1 randomized, double-blind, placebo-controlled, phase 3 study of nirsevimab, in healthy-term and late-preterm (i.e.
View Article and Find Full Text PDFJ Cardiothorac Surg
December 2024
Department of Cardiology, Barzilai Medical Center, The Ben-Gurion University of the Negev, Hahistadrout 2, 7830604, Ashkelon, Israel.
Int J Cardiol
December 2024
Jesselson Integrated Heart Center, The Eisenberg R&D Authority, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
J Clin Med
February 2024
Jesselson Integrated Heart Center, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel.
Nat Commun
April 2024
Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
J Cardiovasc Pharmacol
June 2024
Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences. While rupture of vulnerable plaques has been extensively studied, a distinct mechanism known as plaque erosion (PE) has gained recognition and attention in recent years. PE, characterized by the loss of endothelial cell lining in the presence of intact fibrous cap, contributes to a significant and growing proportion of acute coronary events.
View Article and Find Full Text PDFJ Pediatric Infect Dis Soc
February 2024
Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
J Am Geriatr Soc
December 2023
Medical School for International Health, The Ben-Gurion University of the Negev, Beer-Sheva, Israel, Israel.
Clin Cardiol
January 2024
Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
J Clin Med
September 2023
Department of Cardiology, Barzilai Medical Center, The Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Background: Vasopressors are frequently utilized for blood pressure stabilization in patients with cardiogenic shock (CS), although with a questionable benefit. Obtaining central venous access is time consuming and may be associated with serious complications. Hence, we thought to evaluate whether the administration of vasopressors through a peripheral venous catheter (PVC) is a safe and effective alternative for the management of patients with CS presenting to the intensive cardiovascular care unit (ICCU).
View Article and Find Full Text PDFNat Commun
July 2023
Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Sci Data
June 2023
Alberta Children's Hospital Research Institute, University of Calgary, 28 Oki Dr NW, Calgary, AB, T3B 6A8, Canada.
Clin Infect Dis
October 2023
Merck & Co., Inc., Rahway, New Jersey, USA.
Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
View Article and Find Full Text PDFStem Cell Res Ther
June 2023
The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, National Institute for Biotechnology in the Negev, The Ben-Gurion University of the Negev, 84105, Beer Sheva, Israel.
Adult hematopoietic stem cells (HSCs) in the bone marrow (BM) are quiescent. Following perturbations, such as blood loss or infection, HSCs may undergo activation. Surprisingly, little is known about the earliest stages of HSCs activation.
View Article and Find Full Text PDFVaccine
May 2023
MSD (UK) Limited, London, United Kingdom.
Background: V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa-HBV-IPV/Hib and rotavirus RV1 vaccines.
Methods: V114 and PCV13 were administered in a 2+1 schedule at 2, 4, and 11-15 months of age.
Diagnostics (Basel)
March 2023
School of Health Sciences, The Ben-Gurion University of the Negev, Beer-Sheba 84105, Israel.
ACS Appl Mater Interfaces
April 2023
Zuckerberg Institute for Water Research, The Jacob Blaustein Institutes for Desert Research of the Ben-Gurion University of the Negev, Campus Sde Boker, Midreshet 84990, Israel.
Virus removal from water using microfiltration (MF) membranes is of great interest but remains challenging owing to the membranes' mean pore sizes typically being significantly larger than most viruses. We present microporous membranes grafted with polyzwitterionic brushes (-dimethylammonium betaine) that combine bacteriophage removal in the range of ultrafiltration (UF) membranes with the permeance of MF membranes. Brush structures were grafted in two steps: free-radical polymerization followed by atom transfer radical polymerization (ATRP).
View Article and Find Full Text PDFUltrason Sonochem
May 2023
Department of Chemistry, Nuclear Research Center-Negev, P.O. Box 9001, Be'er-Sheva 84190, Israel; Department of Civil and Environmental Engineering, the Ben-Gurion University of the Negev, Be'er-Sheva, Israel. Electronic address:
This review article summarizes the comprehensive work that was done in our laboratory in recent years, as-well-as other reports, on the various aspects of sonochemistry of molten gallium. The low m (29.8 °C) of gallium enables its melting in warm water, aqueous solutions and organic liquids.
View Article and Find Full Text PDFBMC Geriatr
March 2023
Jesselson Integrated Heart Center, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
AIDS
July 2023
Merck & Co., Inc., Rahway, New Jersey, USA.
Objectives: To evaluate the safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children with HIV.
Design: This phase 3 study (NCT03921424) randomized participants 6-17 years of age with HIV (CD4 + T-cell count ≥200 cells/μl, plasma HIV RNA <50 000 copies/ml) to receive V114 or 13-valent PCV (PCV13) in a double-blind manner on Day 1, followed by PPSV23 at Week 8.
Methods: Adverse events (AEs), pneumococcal serotype-specific immunoglobulin G (IgG), and opsonophagocytic activity (OPA) were evaluated 30 days after each vaccination.
Hum Vaccin Immunother
December 2023
Merck & Co., Inc., Rahway, NJ, USA.
Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-risk adults. This subgroup analysis from a phase 3 study evaluated the safety, tolerability, and immunogenicity of sequential administration of either V114 (a 15-valent PCV containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) or PCV13, followed 6 months later by PPSV23, in immunocompetent adults 18-49 years of age with pre-defined risk factors for pneumococcal disease.
View Article and Find Full Text PDFVaccine
April 2023
MSD (UK) Limited, London, United Kingdom.
Background: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F.
Methods: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly.
Angew Chem Int Ed Engl
March 2023
State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350108 (P. R., China.
Poly (triazine imide) photocatalysts prepared via molten salt methods emerge as promising polymer semiconductors with one-step excitation capacity of overall water splitting. Unveiling the molecular conjugation, nucleation, and crystallization processes of PTI crystals is crucial for their controllable structure design. Herein, microscopy characterization was conducted at the PTI crystallization front from meso to nano scales.
View Article and Find Full Text PDFVaccine
January 2023
Merck & Co., Inc., Rahway, NJ, USA.
Background: Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F.
View Article and Find Full Text PDF